9% growth masks hospital margin squeeze; Gurgaon breakout doesn't offset core pressure
Revenue is on track for double-digit FY27, but the quarter exposed deep cracks: hospital EBITDA margin fell 130 bps YoY to 18.2%, missing the 20% target. Worse, PAT collapsed 24.9% QoQ while revenue fell only 5.4% — a leverage inversion that management never explained.
-5.4%
Sequential softness
-24.9%
4x the revenue decline
18.2%
vs 19.5% prior year, vs 20% target
On the headline, Shalby delivered 9.7% YoY revenue growth and 8.3% PAT growth — steady enough. But read the quarter sequentially and the picture inverts: revenue fell 5.4% QoQ, and profit crashed 24.9% QoQ. That 4x leverage collapse — where revenue barely declined but profit halved — signals either one-time Q2 costs or a procedure mix shift. Management didn't explain it, only deferred margin benefits to Q4.
The deeper issue is the hospital business. Stand-alone EBITDA margin compressed to 18.2% from 19.5% a year ago — a 130 bps erosion — while management is still publicly targeting 20% for FY27. That gap is no longer a rounding error. With occupancy at 52% and ARPOB growth only 4.3% YoY, the core franchise is not earning to its own guidance.
What held up on the call, and what didn't
Hospital business remains core, profitable activity with significant headroom
OverstatedStand-alone margin 18.2% vs 19.5% YoY (−130 bps); target 20% now at risk
Gurgaon unit delivering strong growth trajectory, approaching breakeven
SupportedRevenue ~₹30 Cr (+50% YoY); EBITDA positive 2 consecutive quarters; occupancy 55%; ARPOB ₹96k (+18% YoY)
ROCE expansion progressing toward 11-13% industry standard
ContradictedAnnualized ROCE 9.4%; below guidance, no recovery timeline
MedTech targeting double-digit EBITDA margins post-regulatory changes
OverstatedEBITDA positive 5 consecutive quarters; no margin % disclosed; path to double-digit margins unquantified
Margin support expected from operational efficiencies and new supply chain model
PartialEBITDA margin flat YoY at 14.6% vs 15.9%; hospital margin compressed despite efficiency initiatives
What changed vs. the prior quarter
Gurgaon unit accelerating upward
Revenue ~₹30 Cr (+50% YoY); EBITDA positive for 2 consecutive quarters; occupancy 55%; targeting PBT breakeven by Q3/Q4 FY27
Hospital margin pressured downward
Stand-alone margin 18.2% vs 19.5% YoY (−130 bps); vs 20% guidance target, now at risk. Cost pressures cited but no specific recovery timeline
ROCE guidance miss confirmed
Annualized ROCE 9.4% vs prior 11-13% target. Capex ROI deferred; no improvement timeline disclosed
MedTech profitability inflection
5th consecutive quarter EBITDA positive; consolidated Q2 EBITDA ₹3.6 Cr vs ₹1.6 Cr Q1. Still no path to double-digit margins quantified
The bull-bear ledger
Gurgaon 50% growth; EBITDA positive 2 consecutive quarters — genuine execution on the new platform
MedTech EBITDA positive 5 consecutive quarters; new supply chain reducing COGS 30-40%; prior ₹165 Cr loss turning into margin contribution
Net debt declining (₹458 Cr vs ₹554 Cr YoY); gearing 0.45x; capex disciplined at ₹10 Cr per half
Occupancy rising to 52% from 48% YoY; specialist network expanding; ALOS improved to 3.58 days; runway for leverage
Hospital margin compressed 130 bps YoY; target of 20% now at risk; no clear path to recovery articulated
PAT -24.9% QoQ while revenue -5.4% QoQ; Q2-specific headwinds never explained; profit volatility higher than implied
ROCE at 9.4% vs 11-13% guidance; capex ROI underperforming or leverage limiting returns; no recovery timeline
MedTech: no quantified path to double-digit margins; management deferred numbers; turnaround narrative still unproven
Strategy ambiguity on hospital vs. MedTech vs. Gurgaon; hospital-only capex allocation not disclosed; analyst pushback deflected
Risks, ranked by holder concern
Hospital margin compression continues; 20% target now at risk
HighCore profit engine losing leverage. Margin fell 130 bps YoY and is tracking below guidance. If compression persists into Q3/Q4, the hospital thesis breaks and normalization of multiples likely.
ROCE below 11-13% guidance with no recovery timeline
HighSignals capex ROI underperforming or debt burden limiting returns. If capex cycles higher without ROI recovery, leverage rises and equity returns compress.
QoQ PAT collapse (-24.9% vs -5.4% revenue) unexplained; structural weakness possible
HighIf Q2 cost pressures repeat, profit power is structurally lower than guided. If one-time, timing matters — but silence on the call raises credibility doubt on near-term visibility.
MedTech: no clear path to double-digit EBITDA margins disclosed
MediumPrior ₹165 Cr loss; EBITDA positive but small (₹3.6 Cr). Management evasion ('unable to give you numbers') on roadmap raises doubt on execution confidence and turnaround credibility.
Gurgaon unit dependency; PBT breakeven by Q3/Q4 FY27 is tight timeline
MediumUnit is only ~10% of hospital revenue; 50% growth is impressive but scale still small. If occupancy growth stalls or costs rise, breakeven gets pushed and capex ROI declines.
Hospital occupancy at 52% still below potential; execution risk if improvement slows
MediumManagement claims '50% revenue upside at full utilization,' but occupancy growth has only +400 bps YoY and momentum is unclear. If occupancy stalls, margin recovery thesis loses its key lever.
NPPPA drug capping effective mid-November 2026; oncology margin risk
LowManagement expects limited impact (medicines bundled in surgeries), but if implementation is stricter or affects implant-related pharma, margins compress unexpectedly.
How the street is positioned
The stock has lost 65% from its all-time high of ₹339.5 and is now trading at ₹118.35, well below all three major simple moving averages (SMA20 ₹123.35, SMA50 ₹135.86, SMA200 ₹155.05). The RSI at 35.9 shows weak momentum. Near the 52-week low of ₹110.61, the stock has recovered 7% off lows but is still deeply beaten. This drawdown prices in either structural profit loss or a permanent de-rating of multiples.
On the ownership side, FII holdings are steady at 4.46% (up 0.1pp from Q1), and promoter is locked in at 74.33%. No material selling pressure from institutions; if anything, the slight FII uptick suggests some accumulation at depressed levels. But the framing remains cautious — no enthusiastic call from any major holder yet.
The paradox is stark: the stock is cheap by absolute valuation (near 52-week low), but the quarter's miss on hospital margin guidance and the unexplained QoQ PAT collapse have shattered execution credibility. The 65% loss from ATH is no longer speculative froth; it's pricing in a permanent earnings reset. This quarter — rather than sparking a relief bounce — reinforced the bear thesis: hospital margins are compressing, not recovering, and management has no clear answer.
The debate
What to watch next
1 · Hospital EBITDA margin stabilizes or improves
Must recover to at least 19%+ in Q3 to restore guidance credibility. Current 18.2% and compressing trend (three quarters down) signals structural pressure, not cyclical. If margin continues lower into Q3, the 20% target is abandoned and re-rating accelerates.
2 · Gurgaon unit achieves PBT breakeven by Q3/Q4 FY27
Management's tight guidance on this timeline will determine execution credibility on the new platform. Occupancy at 55% has room to run; if it slows or costs rise, breakeven slips and capex ROI questions deepen.
3 · MedTech supply chain cost benefits flow through in H2 FY27
Management promised 30-40% COGS reduction and targeted full benefits by Q4. Consolidated EBITDA doubled from Q1 to Q2 (₹1.6 Cr → ₹3.6 Cr), but margins are still small. H2 results will show if the turnaround is real or just seasonal volatility.
Shalby is at an inflection point: the old hospital-only story is compressing (margin, ROCE), but the new multi-platform story (Gurgaon, MedTech) is still too small to carry earnings. This quarter exposed the gap. Gurgaon is genuine progress, but at ₹30 Cr revenue (~10% of hospital base), it cannot yet offset hospital margin erosion.
The single number to track from here is hospital EBITDA margin. At 18.2% and falling, it is below guidance and raising doubt on whether management's efficiency and specialist expansion thesis is real execution or just talk. If margin stabilizes or improves in Q3/Q4, the bull case holds and the stock finds support. If it compresses further, the 65% loss from ATH was only the first leg of re-rating.
Rating: Hold. The debate is unresolved; execution in Q3/Q4 FY27 will decide whether this is a cyclical stumble (opportunity) or a structural reset (risk).
Informational and educational content only. Not investment advice.